TuarascÃ¡lacha RannÃ¡n na SeirbhÃsÃ - St. James's Hospital

More documents

Recommendations

Info

FoilseacháinRichardson, KJ O’Byrne.Epidermal growth factor receptor (EGFR) andCyclooxygenase (COX)-2 in non-small cell lungcancer (NSCLC). Growth factors and cytokinesenhance the in vitro anti-tumour activity of selectiveEGFR and/or COX-2 inhibitors.Proc Am Soc Clin Oncol 2003: 22: abstract 2629(Poster)C Richardson, D Swinson, D Richardson, W A Swain, KJO’Byrne.Phase II open-label study of MEN 10755 in patientswith small cell lung cancer extensive disease (SCLC-ED).Proc Am Soc Clin Oncol 2003; 22: abstract 2829N Dickgreber, T Welte, A Gillissen, D Dunlop, WEberhardt, T Wagner, D Swinson, A Capriati, K J O’ByrneTolerability of the novel oral thalidomide analog CC-5013 demonstrating extensive immune activationand clinical response.Proc Am Soc Clin Oncol 2003; 22: abstract 2862 (Posterdiscussion)R Sharma, J Marriott, I Clarke, L Cohen, W Steward, KJO’Byrne, A DalgleishMicroarray analysis of mesothelial cells treated withcrocidolite, erionite, IL-1beta and TNF-alpha. (Oralpresentation World Conference on Lung Cancer[WCLC])Lung Cancer 2003; 41 (suppl 2): S25W Swain, L Sander, T Gant, S Faux, KJ O’ByrneImproved quality of life with the addition of SRL172(killed mycobacterium vaccae) to standardchemotherapy in patients with advanced non-smallcell lung cancer: Phase III results. (Oral presentationWCLC)Lung Cancer 2003; 41 (suppl 2): S35M O’Brien, H Anderson, E Khaukel, KJ O’Byrne, MPawlicki, J Von Pawel, M ReckClinical Evaluation of gefitinib (Iressa ZD1839) incombination with Rofecoxib in cisplatin pre-treatedrelapsed non-small cell lung cancer. (Oralpresentation WCLC)Lung Cancer 2003; 41 (suppl 2): S36KJ O’Byrne, L Clarke, D Dunlop, M Ranson, S Danson, NBotwood.Tumour necrosis factor-alpha cell signalling events inhuman bronchoepithelial cells. (Oral presentationWCLC)Lung Cancer 2003; 41 (suppl 2): S43W A Swain, KJ O’Byrne.D Dunlop, D Roitman, Y Alan, D Walde et al. Resultsof phase II trial of EGF-P64 vaccine in patients withadvanced non-small cell lung cancer. (Oralpresentation WCLC)Lung Cancer 2003; 41 (suppl2): S47M Vincent, C Smith, R Milroy, KJ O’Byrne,Randomised Phase II clinical trial of cetuximab incombination with cisplatin and vinorelbine orcisplatin and vinorelbine alone in patients withadvanced epidermal growth factor receptor (EGFR)-positive non small cell lung cancer (NSCLC). (Oralpresentation); ECCOLung Cancer 2003; 41 (suppl 2): S72R Rosell, M Constenla, R Kolb, W Pfeiffer, KJ O’Byrne, RPirker et al.Selective Cyclooxygenase (COX)-2 inhibitors incombination with cytokines induce growth arrest innon-small cell lung cancer lines at clinically relevantdoses.Lung Cancer 2003; 41 (suppl 2): S174 (Poster WCLC)C Richardson, D Swinson, D Kaur, A Shah, D Richardson,KJ O’Byrne.The expression and prognostic significance of Aktand phosphorylated Akt (pAkt) in non-small cell lungcancer.Lung Cancer 2003; 41 (suppl 2): S212 (Poster WCLC)A Shah, C Richardson, D Richardson, W A Swain, DSwinson, KJ O’Byrne.Hypoxia inducible factor-1 alpha in non-small celllung cancer: Relation to other biological factors andprognosis.Lung Cancer 2003; 41 (suppl 2): S214 (Poster WCLC).D Swinson, L Jones, G Cox, D Richardson, A Harris, KJO’ByrneThe History of Bone Marrow Transplantation.In; History of Organ and Cell Transplantation. Eds NSHakim and VE Papalois. Imperial College Press. 2003.McCann S.Vascular endothelial growth factor in lung cancerLung Cancer edited by Barbara Driscoll. Humana Press(2003), Volume 1, section E, chapter 21, pp357-374.84 84
FoilseacháinO'Byrne KJ, Goddard J, Giatromanolaki A, KoukourakisMI inChapter on Low Grade LymphomasHigh dose chemotherapy : principles and practiseEdited by E Vandenberghe and P LoriganPublished by Martin DUnitzSomatic gene therapy, paradigm shift of Pandora’sbox ; a perspective on gene therapy. Manufacturingof gene therapeutics, methods, processing regulationand validationEd G Subramanian Kluwer Academic/PlenumPublishers NY pp1-16 (Invited Chapter).Lawler M (2003)Gene therapy for cancer; deceiving the malignantcell. Manufacturing of gene therapeutics, methods,processing regulation and validationEd G Subramanian Kluwer Academic/PlenumPublishers NY pp17-32 (Invited Chapter).Lawler M (2003)STIÚRTHÓIREACHT SAMSDermatology:Xp 22.3 microdeletion in a 19 year old girl withclinical features of MLS syndrome.Paediatric Dermatology Mar/April 2003; vol 20 No 2:153-157Enright F, Campbell P, Stallings R, Halls K, Green A,Sweeney E, Barnes L, Watson R.Dermatomyositis associated with angiotropiclymphoma.Clinical & Experimental Dermatology 2003;28, 597 –599.Langan SM, O’Briain S, Barnes L.Topical costicosteroid treatment: systemic sideeffects.Br J of Dermatology 2003;149:417.Kane D, Barnes L, FitzGerald O.Epithelial corneal dystrophies. In: Cornea:Dystrophies and Degenerations: A MolecularGenetics Approach, (Wang M, Flatten N, Eds)American Academy of Ophthalmology 2003, (ISBN: 1-5605-5277-8) pp19-43Irvine AD, McLean. WHIHereditary disorders of the skin.In Encyclopaedia of the Human Genome, (Cooper DNEd) Nature Publishing Group, London, 2003, vol. 3, pp.153-159Corden L, McLean WHI, Irvine AD.The genetics of hair loss. In Encyclopaedia of theHuman Genome.(Cooper DN Ed) Nature Publishing Group, London,2003, vol. 5, pp. 314-325Irvine AD.An unusual N-terminal deletion of the laminin 3aisoform leads to the chronic granulation tissuedisorder laryngo-onycho-cutaneous syndrome.Human Molecular Genetics 2003, 12: 2395-2409McLean WHI, Irvine AD, Hamill KJ, Whittock NV,Coleman CM, Mellerio JE, Ashton GS, Dopping-Hepenstal PJH, Eady RAJ, Jamil T, Phillips RJ, Shabbir SG,Haroon TS, Khurshid K, Moore JE, Page B, Darling J,Atherton DJ, Munro CS, Smith FJD, McGrath JA.The Molecular Genetics of The Genodermatoses:Progress To Date And Future Directions.British Journal of Dermatology 2003, 148: 1-13Irvine AD and McLean WHI.Absence of RECQL4 mutations in poikiloderma withneutropenia in Navajo and non-Navajo patients.American Journal of Medical Genetics 2003, 118:299-301Wang LL, Gannavarapu A, Clericuzio CL, Erickson RP,Irvine AD, Plon SERaised limb bands developing in infancy.British Journal of Dermatology 2003, 149:436-7Paller AS, Irvine AD, Russi DC.Association between long-term acitretin therapy andosteoporosis: no evidence of increased risk.Clinical and Experimental Dermatology 2003, 28: 307-9McMullen EA, McCarron P, Irvine AD, Dolan OM, AllenGE.GUIDeAssessing limiting factors to the acceptance ofantiretroviral therapy in a large cohort of injectingdrug users.HIV Med 2003 Jan; 4 (1): 33-7Clarke S, Delamere S, McCullough L, Hoskins S, Bergin8585
Page 1 and 2:
LeathanachRIALACHAS AGUS FEIDHMÍOC
Page 3 and 4:
ComhaltaíBhord an OspidéilCOMHALT
Page 5 and 6:
FoireannComhairleoireachtaAn Docht
Page 7 and 8:
TuarascálachaCorparáideachabhaine
Page 9 and 10:
TuarascálachaCorparáideachafaoi d
Page 11 and 12:
TuarascálachaCorparáideachaleo as
Page 13 and 14:
PríomhthoirteannaGníomhaíochtaIo
Page 15 and 16:
PríomhthoirteannaGníomhaíochtaR
Page 17 and 18:
Tuarascálacha Rannán Corparáidea
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
IMSCorporate Division ReportsRannó
Page 25 and 26:
Bainistíocht ÁbharCórais Bhainis
Page 27 and 28:
Tuarascálacha Rannán na Seirbhís
Page 29 and 30:
Page 31 and 32:
Page 33 and 34: Tuarascálacha Rannán na Seirbhís
Page 47 and 48: Stiúrthoireachtaí Seirbhísí Cli
Page 75 and 76: Tuarascalacha chláir Rannóg75
Page 77 and 78: Tuarascalacha chláir RannógTionsc
Page 79 and 80: FoilseacháinFOILSEACHÁINCOTHÚ CL
Page 81 and 82: FoilseacháinImpact of the Media on
Page 83: FoilseacháinA, Chopra R, Davies A,
Page 87: Foilseacháindeletion presenting as
show all

TuarascÃ¡lacha RannÃ¡n na SeirbhÃ­sÃ­ - St. James's Hospital

Create successful ePaper yourself

Delete template?

Save as template?

TuarascÃ¡lacha RannÃ¡n na SeirbhÃsÃ - St. James's Hospital